Genflow Biosciences Share Discussion Threads

[moneymunch] 04/9/2024 15:37

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,714 followers
3h

Last week's Annual Aging Research & Drug Discovery Meeting was a triumph! Investors and peers alike had the opportunity to learn more about Genflow Biosciences (LON:GENF) (OTCQB:GENFF) latest #SIRT6 research.

Learn more about #Genflow's innovative work:

#aging #longevity #MASH #GENF #GENFF

[moneymunch] 29/8/2024 16:01

You can read the majority of the Poster Presentation if you click on the Linkden post and Zoom into the photograph of the poster. Gla ;-)))

"Human centenarian-associated Sirt6 mutants counteracts hepatic steatosis and fibrosis"

Conclusions

Sirt6, and more specifically Sirt6c, could reduce hepatic lipid accumulation and fibrotic phenotypes, such collagen secretion and deposition in HSC, as well as decrease stiffness in hepatocytes.

[moneymunch] 29/8/2024 15:10

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)’s Post

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,709 followers
3h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s poster presentation at the 11th Annual Aging Research and Drug Discovery Meeting has been a standout success!

The company is showcasing its groundbreaking #SIRT6 research, which is sparking significant interest at the conference.

Stay tuned for more updates!

#biotech #aging #GENF #GENFF

[bri15] 29/8/2024 13:09

North it will be tomorrow.

[northeast14] 28/8/2024 21:43

One day soon 🚀

[moneymunch] 28/8/2024 19:54

🧬 "Stay tuned for more updates"

Tick,Tock, can't be too much longer before take off, Excitement building!!! Gla holders :-)

[moneymunch] 26/8/2024 14:05

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,704 followers
2h

🎉 Kickoff Alert!

Today marks the start of the 11th Annual #Aging Research and Drug Discovery Meeting. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr. Eric Leire spoke about the company's lastest #SIRT6 research and discussed its implications on #MASH.

🧬 Stay tuned for more updates!

[smithie6] 25/8/2024 20:45

...well, some us sometimes have to do things !

& haven't time to read conference notes or watch a 1 hour presentation

...& we'd be grateful if those that do have the time could include a brief conclusion at the end of any long post to help highlight what the significance to GENF is of such & such medical article. And also since many of us could not deduce what the relevance might be even if we had the time to read medical articles or watch 1 hour long presentations.

[moneymunch] 24/8/2024 22:21

Ps Smithie, although we haven't had any official news since June, there's obviously significant research in progress, highlighted by the PubMed scholarly publication which details Genflow's centenarian Sirt6 mutation for obesity, combined with the potential implication of University of Rochesters research , which no doubt will be shared in next week's high profile conference. I don't think you need a great understanding of the science but it's always advisable to read as much relevant information as you can on wherever you're invested, to enable to make your own important investment decisions without being influenced too much by others. As far as I'm concerned, the stuff I've recently posted is highly significant to my investment and hopefully to those who already hold, and although no guarantees, suggest that Genflow's potential and prospects could be absolutely huge. Gl :-)

[moneymunch] 24/8/2024 20:22

Lol...Genflow are all set towards the brink of greatness and those invested heavily are set for transformational returns. Gl :-)

[smithie6] 24/8/2024 20:13

moneymunch

your recent posts imo don't mean anything at all to most of us PIs.

And 95% of us PIs won't even bother to try to read the text of your posts....since most of us do not understand the detailed pharma stuff. We are not pharma lab workers.

-+--

Can you post a conclusion to each post, ...ie. what point are you making in that post ??

[moneymunch] 24/8/2024 07:33

No reference to Sirt6 from Vera and co at University of Rochester, but there is in the abstract posted below this article and so fingers crossed this is related to Genflow's following linkedin post, where Vera is also presenting at this coming weeks conference, Gla holders.....Exciting times!!! ;-)

" Exciting news from Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

Next week, #Genflow will share the company's latest revolutionary #SIRT6 work at the 11th Annual Aging Research & Drug Discovery Meeting"


Scientists discover longevity genes.

Here's how it can extend lifespan of humans

Aug 22, 2024.

For generations, humans have tried to find the elixir which can extend their lives beyond their natural limit and deceive death.

Now, scientists have made a discovery of a gene which has brought humanity very close to this impossible target of achieving longevity.

The gene has been found to possess the capability of promoting cellular repair and reducing the effects of ageing. This discovery has taken the scientific community close to finding methods for extending not just long but healthy lives.

Scientists are now understanding the mechanisms behind this particular longevity gene to find new strategies which can bring significant change in human ageing and lifespan.

The study was carried out by the University of Rochester's team of scientists which comprised Doris Johns Cherry Professor of Biology and Medicine Vera Gorbunova and Professor of Biology Andrei Seluanov.

The Rochester researchers made the dramatic discovery after making a stunning observation of the naked mole rats.

Scientists found that these critters have long lifespans and are able to resist age-related diseases. These rodents are able to survive for nearly 41 years, which is almost a decade longer in comparison to the lives of rodents of their size.
What can this longevity gene do in the human body?

In the experiments carried out by the researchers, this specific gene was transferred into the bodies of mice.

This gene produces high molecular weight hyaluronic acid or HMW-HA which led to significant improvement in the health of the mice and also increased their lifespan by around 4.4 per cent.

HMW-HA is a sort of mechanism which has a stunning effect on ageing and diseases.

HMW-HA is ten times more in the naked mole rats in comparison to the mice and humans. When the scientists removed it from the naked mole rat cells, the cells had more chances of forming tumours.

HMW-HA has the ability to fend off cancer. It was observed that the modified mice were able to protect themselves from spontaneous tumours as well as chemically induced skin cancer.

It was also noted that they suffered less inflammation, which is a sign of ageing, and had a healthier gut.

This discovery has now brought humans to the threshold of improving lifespan and health while reducing inflammation-related diseases in them.

..........

Mechanisms of longevity in the naked mole rat: high molecular weight hyaluronan and stable epigenome.
Seluanov, Andrei
University of Rochester, Rochester, NY, United States

Our aims are: (1) Complete the lifespan study and characterize cancer susceptibility, tissue pathology, genome stability (with Project 3), metabolism, and methylation age (with Project 4) of nmrHAS2 mice. (2) Perform a high throughput screen for hyaluronidase inhibitors and test the effect of these compounds on health, fitness and age- related pathologies in mice. (3) Determine molecular mechanisms responsible for NMR epigenome stability. We will identify specific histone modifying enzymes that are differentially regulated in the NMR, and manipulate them to stabilize the mouse epigenome. We will collaborate with Project 1 to determine the role of SIRT6 in NMR epigenome stability, and with Project 3 to investigate genome and methylome stability in the NMR and mouse cells after epigenetic interventions. The proposed research will identify strategies for exporting the longevity mechanisms found in the naked mole rat to other species.

[moneymunch] 21/8/2024 17:36

.......

Announcing Longevity Science Foundation as tier 5 sponsor of ARDD 2024

Empowering the future of aging research: Longevity Science Foundation to sponsor ARDD 2024, the world's largest conference on aging research in the biopharmaceutical industry

Business Announcement

Aging Research and Drug Discovery

The University of Copenhagen is excited to announce Longevity Science Foundation as a Tier 5 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online.

..........

ARDD 2024 is set to feature a stellar lineup. The Longevity Science Foundation, along with esteemed academic institutions, clinicians, industry leaders, investors, and pharmaceutical companies, will contribute to rich dialogues and present new research in the field of aging. This year, ARDD is proud to be a partner of XPRIZE Healthspan, a 7-year, $101 million global competition to revolutionize the way we approach human aging. Highlighting this collaboration, XPRIZE Healthspan will host its first XPRIZE Healthspan Team Summit at the 11th ARDD. The event underscores a shared commitment between ARDD and XPRIZE to fostering advancements in health and longevity, signaling an important milestone in efforts to enable everyone to live healthier and longer lives through extended healthspan.

“I’m extremely excited about this year's ARDD. We have a stellar academic lineup and an incredibly strong presence from leading companies in the aging field. This year the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and many others have been strengthened and we are super excited that XPRIZE will host their XPRIZE Healthspan Team Summit at ARDD.

[moneymunch] 21/8/2024 17:28

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,701 followers
5h

🧬 Exciting news from Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

Next week, #Genflow will share the company's latest revolutionary #SIRT6 work at the 11th Annual Aging Research & Drug Discovery Meeting .

Learn more about #GENF's groundbreaking work:

#GENF #GENFF #MASH #longevity #healthspan

[moneymunch] 15/8/2024 08:03

Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs

Aug 13, 2024

Key Points

Treating aging and its consequences will be a colossal market.
The first seeds of the coming boom have already been planted.

Motley Fool Issues Rare “All In” Buy Alert

Investing based on the segment's long-term prospects is likely to be very lucrative.

I predict that a gold rush in longevity medicines is going to start in the next half-decade or so. That's right: Biotech and pharma companies are going to try developing drugs that can extend human lifespan. And eventually, they're going to succeed, at least somewhat.

The early competitors are already getting down to work. Soon enough, there will surely be great opportunities for investment -- as well as a sea of opportunities to lose your money. Here's a road map for how to invest in the best companies within this new area of medicine, starting with an overview of the playing field as it is today.

Picking up momentum

The second phase is when most investors will start to hear a lot about longevity-promoting medicines in development. Expect biotechs, especially micro caps that are too "out there" to have backing from traditional biopharma venture capital, to be where the majority of the activity occurs.

[moneymunch] 14/8/2024 08:46

Back on track, UPward momentum in anticipation of a run of positive newsflow and potential significant re-rate, expected soon!!! Gla holders :-)

[aberdeano] 06/8/2024 12:33

Gene therapy is revolutionizing the future of medicine, offering new possibilities for treating a range of genetic disorders. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we are at the front of this groundbreaking field, using the power of genetic engineering to enhance human health and longevity.

Our latest advancements in gene therapy have been on the hashtag#SIRT6 gene, known for its role in extending hashtag#healthspans and treating age-related diseases. By leveraging the power of hashtag#SIRT6, we aim to provide solutions for a healthier, longer life.

Key highlights of Genflow’s gene therapy program include:

✅ Precision Medicine: Tailoring treatments to individual genetic profiles for maximum efficacy.
✅ Cutting-Edge Research: Using latest technologies to advance the application of gene therapy.
✅ Transformative Impact: Offering potential cures for previously untreatable genetic conditions.

[moneymunch] 01/8/2024 06:23

Vera Gorbunova & Eric Verdin are both presenting. Gla ;-)



.......

Announcing Longevity Science Foundation as tier 5 sponsor of ARDD 2024

Empowering the future of aging research: Longevity Science Foundation to sponsor ARDD 2024, the world's largest conference on aging research in the biopharmaceutical industry

Business Announcement

Aging Research and Drug Discovery

The University of Copenhagen is excited to announce Longevity Science Foundation as a Tier 5 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online.

..........

ARDD 2024 is set to feature a stellar lineup. The Longevity Science Foundation, along with esteemed academic institutions, clinicians, industry leaders, investors, and pharmaceutical companies, will contribute to rich dialogues and present new research in the field of aging. This year, ARDD is proud to be a partner of XPRIZE Healthspan, a 7-year, $101 million global competition to revolutionize the way we approach human aging. Highlighting this collaboration, XPRIZE Healthspan will host its first XPRIZE Healthspan Team Summit at the 11th ARDD. The event underscores a shared commitment between ARDD and XPRIZE to fostering advancements in health and longevity, signaling an important milestone in efforts to enable everyone to live healthier and longer lives through extended healthspan.

“I’m extremely excited about this year's ARDD. We have a stellar academic lineup and an incredibly strong presence from leading companies in the aging field. This year the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and many others have been strengthened and we are super excited that XPRIZE will host their XPRIZE Healthspan Team Summit at ARDD.

[moneymunch] 31/7/2024 17:32

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,687 followers
6h

Earlier this year, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Biosciences was named “a firm to watch” by @TheGuardian, substantiating the results of their MASH studies this past year.

Dr. Eric Leire, CEO and Founder of Genflow said, “Some people are lucky to have the good gene, and what we want to do is share that luck with everybody.” The “good gene,” refers to #SIRT6, which plays an important role in longer #healthspans.

As Genflow conquers the #biotech world, the company also offers investors an exciting investment case with:

✅Large Market opportunity: 35 million globally, keeping the door open to broaden anti-aging.

✅Long Life IP: two patent families

✅Robust Pipeline: advancing developmental programs

Find more information here:

#genes #longevity #healthspan #GENF

[moneymunch] 31/7/2024 08:31

Big news at anytime, with plenty of positive newsflow expected soon. Gla ;-)

1.20230018934METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023

Int.Class

A61K 48/00

Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

.......

.WO/2024/121363VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

WO - 13.06.2024

Int.Class

A61K 38/43

Appl.No PCT/EP2023/084840

Applicant GENFLOW BIOSCIENCES SRL

Inventor VINCIGUERRA, Manlio

The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease.

......

.4338267VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES

EP - 20.03.2024

Int.Class

H02K 7/18

Appl.No 22808414

Applicant UNIV ROCHESTER

Inventor GORBUNOVA VERA

The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. The invention further provides means for the repair of double strand breaks in a cell. Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.

[moneymunch] 30/7/2024 05:49

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,686 followers
18h

In the world of #biotech, safety must be of the utmost concern. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we have systems in place to enhance safety across our innovative #SIRT6 trials.

Our patent-pending tech allows for non-replicating, safe transient expression of genes, minimizing risks while maximizing potential benefits.

In simpler terms, we have created methods that temporarily activate the crucial SIRT6 gene without permanently altering the DNA, ensuring both safety and efficacy for therapeutic applications.

To learn more about our protocols, click here:
A biotechnological powerhouse for anti ageing treatments | Genflow

[moneymunch] 28/7/2024 07:52

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,684 followers
1w

The biotech market has had another resurgence of interest this year, marked by increased hopes that the first round of interest rate cuts will come soon.

Positioned to capitalize on this are companies in high growth markets, such as Genflow Biosciences (LON:GENF) (OTCQB:GENFF), a leader in aging research, which continues to innovate with its cutting edge #SIRT6 therapeutics.

Read more about the rally: